Navidea Biopharmaceuticals Inc ROCE
¿Qué es el ROCE de Navidea Biopharmaceuticals Inc?
El ROCE de Navidea Biopharmaceuticals Inc es 4,619.50%
¿Cuál es la definición de ROCE?
El retorno sobre el capital empleado (ROCE) es una relación financiera que mide la rentabilidad de una empresa y la eficiencia con la que se utiliza su capital.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE de compañías en Sector Health Care en NYSEMKT en comparadas con Navidea Biopharmaceuticals Inc
¿Qué hace Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Empresas con roce similar a Navidea Biopharmaceuticals Inc
- GTPL Hathway tiene ROCE de 3,515.44%
- VBI Vaccines tiene ROCE de 3,542.31%
- North European Oil Royalty Trust tiene ROCE de 3,719.06%
- Pasofino Gold tiene ROCE de 3,729.38%
- Synthesis Systems tiene ROCE de 3,846.25%
- PhaseBio Pharmaceuticals tiene ROCE de 4,146.52%
- Navidea Biopharmaceuticals Inc tiene ROCE de 4,619.50%
- SRAX Inc tiene ROCE de 4,628.38%
- Blue Apron Inc tiene ROCE de 5,016.13%
- ParkerVision tiene ROCE de 5,589.92%
- Asensus Surgical Inc tiene ROCE de 5,861.92%
- Whiting USA Trust II tiene ROCE de 7,251.43%
- Astra tiene ROCE de 7,618.05%